Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trial (Q48293345)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/24835833

Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/24835833

0 references

chronic obstructive pulmonary disease

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/24835833

1

object named as

Marc Decramer

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

Antonio Anzueto

2

object named as

Antonio Anzueto

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

author name string

Edward Kerwin

3

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/24835833

Thomas Kaelin

4

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/24835833

Nathalie Richard

5

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/24835833

Maggie Tabberer

7

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/24835833

Stephanie Harris

8

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/24835833

Alison Church

9

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/24835833

publication date

14 May 2014

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/24835833

The Lancet. Respiratory medicine

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/24835833

2

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/24835833

6

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/24835833

472-486

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/24835833

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70065-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined treatment with formoterol and tiotropium is more efficacious than treatment with tiotropium alone in patients with chronic obstructive pulmonary disease, regardless of smoking status, inhaled corticosteroid use, baseline severity, or gender

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70065-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70065-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70065-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70065-7

7 January 2021

based on heuristic

inferred from DOI database lookup

28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70065-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70065-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70065-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70065-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Performance of American Thoracic Society-recommended spirometry reference values in a multiethnic sample of adults: the multi-ethnic study of atherosclerosis (MESA) lung study

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70065-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Spirometric reference values from a sample of the general U.S. population

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70065-7

7 January 2021

based on heuristic

inferred from DOI database lookup

MRC chronic Dyspnea Scale: Relationships with cardiopulmonary exercise testing and 6-minute walk test in idiopathic pulmonary fibrosis patients: a prospective study

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70065-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70065-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70065-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of the Shortness of Breath with Daily Activities questionnaire (SOBDA).

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70065-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Item selection, reliability and validity of the Shortness of Breath with Daily Activities (SOBDA) questionnaire: a new outcome measure for evaluating dyspnea in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70065-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Shortness of Breath with Daily Activities questionnaire: validation and responder thresholds in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70065-7

7 January 2021

based on heuristic

inferred from DOI database lookup

St. George's Respiratory Questionnaire: MCID

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70065-7

7 January 2021

based on heuristic

inferred from DOI database lookup

MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70065-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple significance tests: the Bonferroni method

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70065-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Meaningful effect size and patterns of response of the transition dyspnea index

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70065-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70065-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70065-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70065-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70065-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70065-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70065-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(14)70065-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2213-2600(14)70065-7

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/24835833

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/24835833

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48293345&oldid=1419386376"